eRAM
encyclopedia of Rare Disease Annotation for Precision Medicine
| Disease | multiple myeloma |
| Comorbidity | C0376358|prostate cancers |
| Sentences | 1 |
| PubMedID- 22409262 | Patients/methods: subjects receiving either first-line or second-line chemotherapy for advanced or metastatic lung, breast, gastrointestinal, bladder, ovarian or prostate cancers, cancer of unknown origin, myeloma or selected lymphomas were randomized to 5 mg, 10 mg or 20 mg once daily of apixaban or placebo in a double-blind manner for 12 weeks. |
Page: 1